Mineralys Therapeutics, Inc. MLYS Common stock, par value (in dollars per share)
Common stock, par value (in dollars per share) at other companies
Other financials
Where this comes from
Reported directly by Mineralys Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CommonStockParOrStatedValuePerShare.
The official record: Mineralys Therapeutics, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Mineralys Therapeutics, Inc.'s common stock, par value (in dollars per share).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Mineralys Therapeutics, Inc.'s common stock, par value (in dollars per share)?
- Mineralys Therapeutics, Inc. (MLYS) reported common stock, par value (in dollars per share) of $0 in Q1 2026.
- How has Mineralys Therapeutics, Inc.'s common stock, par value (in dollars per share) changed year-over-year?
- Mineralys Therapeutics, Inc.'s common stock, par value (in dollars per share) decreased by 0.0% year-over-year, from $0 to $0.
- What is the long-term trend for Mineralys Therapeutics, Inc.'s common stock, par value (in dollars per share)?
- Over 3 years (2022 to 2025), Mineralys Therapeutics, Inc.'s common stock, par value (in dollars per share) has grown at a 0.0% compound annual growth rate (CAGR), from $0 to $0.